Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours
Ce dossier présente un ensemble d'articles concernant la prise en charge des cancers durant la crise sanitaire liée au COVID-19
Patients with cancer are at an increased risk of severe COVID-19. Breakthrough infections after two vaccinations do occur and can be lethal. Most patients treated for a solid tumour develop an adequate humoral response against SARS-CoV-2 after two vaccinations; however, antibody concentrations tend to be lower when vaccinations are administered during chemotherapy, resulting in a suboptimal response in a small proportion of patients. In addition, binding and neutralising antibody concentrations decrease over time, resulting in a further decrease in immunity. This finding prompted many countries to prioritise these patients for a third vaccination. However, little information is available about the immunogenicity of a third vaccination in patients treated for solid tumours, especially against the currently most prevalent variant, omicron (B.1.1.529).
The Lancet Oncology , commentaire en libre accès, 2021